drugset / Trial / NCT03774615
ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, uncontrolled, monocenter, phase IV study. The aim of this study is to detect AEs or SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks.
Timeline
- Start
- 2019-03-18
- Primary completion
- 2019-11-29
- Completion
- 2019-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric maltol | Small molecule | 30 mg | Oral |